Company Profile

DR. REDDYS LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE3583.15438.35 (+13.94 % )
PREV CLOSE (Rs.) 3144.80
OPEN PRICE (Rs.) 3200.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 81179
TODAY'S LOW / HIGH (Rs.)3200.00 3612.20
52 WK LOW / HIGH (Rs.)2352 3612.2
NSE3583.20 436.4 (+13.87 % )
PREV CLOSE(Rs.) 3146.80
OPEN PRICE (Rs.) 3250.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 3583.20 (2094 )
VOLUME 2367583
TODAY'S LOW / HIGH(Rs.) 3210.00 3615.60
52 WK LOW / HIGH (Rs.)2351.2 3615.6

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.03
Dividend Yield(%) 0.56
TTM EPS (Rs.) 158.73
P/E Ratio 22.57
Book Value (Rs.) 884.04
Face Value (Rs.) 5
MCap (Rs. in Mn) 595419.50
Price/Earning (TTM) 17.31
Price/Sales (TTM) 5.52
Price/Book (MRQ) 4.05
PAT Margin (%) 12.02
ROCE (%) 12.49
Incorporation Year : 1984

Management Info :

K Satish Reddy - Chairman GV Prasad - Managing Director

Registered Office :

Address : 8-2-337,Road No. 3,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040 - 4900 2900

Website : www.drreddys.com

Registrar's Details : Bigshare Services Pvt Ltd
306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital,Raj Bhavan Road,Somajiguda,Hyderabad
Listing : BSE, NSE, MCX, New York
NEWS More
27Mar03-27-2020$Dr. Reddy's board approves borrowing of Rs 2,000 crore via multiple routes Dr. Reddy's board approves b

Dr. Reddy’s Laboratories’ Board of Directors has approved borrowings, either through issuance of commercial papers, debentures, bonds and/or through bank credit lines, term loans including external commercial borrowings, as the company may deem fit, up to an aggregate amount of Rs 2,000 crore, in one or more tranches. 

Further, the board of directors has also approved sale of the Contract Development and Manufacturing Organisation (CDMO) division of Custom Pharmaceutical Services (CPS) business of the Company, to its wholly owned step-down subsidiary -- Aurigene Pharmaceutical Services (APSL), on slump sale basis, for a consideration of $72 million.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy’s Laboratories’ Board of Directors has approved b..
25Mar03-25-2020$Dr. Reddy's Laboratories gains on planning to raise funds through CP Dr. Reddy's Laboratories gai

Dr. Reddy's Laboratories is currently trading at Rs. 2865.15, up by 6.50 points or 0.23% from its previous closing of Rs. 2858.65 on the BSE.

The scrip opened at Rs. 2858.00 and has touched a high and low of Rs. 2920.00 and Rs. 2797.70 respectively. So far 8333 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 3187.00 and Rs. 2497.60 respectively. The current market cap of the company is Rs. 47856.73 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.

Dr. Reddy's Laboratories is planning to raise funds by issuance of Commercial Paper (CP). The meeting of company’s Board of Directors will be held on March 27, 2020 to consider and approve the same.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy's Laboratories is currently trading at Rs. 2865.15, u..
24Mar03-24-2020$Dr. Reddy's Laboratories planning to raise funds through CP Dr. Reddy's Laboratories pla
Dr. Reddy's Laboratories is planning to raise funds by issuance of Commercial Paper (CP). The meeting of company’s Board of Directors will be held on March 27, 2020 to consider and approve the same.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy's Laboratories is planning to raise funds by issuance..
23Mar03-23-2020$Dr. Reddy's shines on launching Pyrimethamine Tablets in US Market Dr. Reddy's shines on launch

Dr. Reddys Laboratories is currently trading at Rs. 2951.85, up by 53.75 points or 1.85% from its previous closing of Rs. 2898.10 on the BSE.

The scrip opened at Rs. 2700.00 and has touched a high and low of Rs. 3187.00 and Rs. 2651.00 respectively.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 3187.00 and Rs. 2497.60 respectively. The current market cap of the company is Rs. 48158.33 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.

Dr. Reddy’s Laboratories has launched Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, approved by the U.S. Food and Drug Administration (USFDA). This product is the only ABrated generic version Daraprim (pyrimethamine) Tablets approved by the USFDA.

Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. The company’s Pyrimethamine Tablets USP, are available in 25 mg dose in bottle count sizes of 30 and 100. The Daraprim (pyrimethamine) brand had U.S. sales of approximately $10 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Laboratories is currently trading at Rs. 2951.85, up..
20Mar03-20-2020$Dr. Reddy's launches Pyrimethamine Tablets in US Market Dr. Reddy's launches Pyrimet

Dr. Reddy’s Laboratories has launched Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, approved by the U.S. Food and Drug Administration (USFDA). This product is the only ABrated generic version Daraprim (pyrimethamine) Tablets approved by the USFDA.

Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. The company’s Pyrimethamine Tablets USP, are available in 25 mg dose in bottle count sizes of 30 and 100. The Daraprim (pyrimethamine) brand had U.S. sales of approximately $10 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddy’s Laboratories has launched Pyrimethamine Tablets U..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit521712773
Gross Profit 6175 17007
Operating Profit 825025381
Net Sales 30440106255
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 16722.05 (5.66%)
M.Cap ( in Cr)
35533.19
Procter&Gamble Healt (BSE)
 4324.60 (11.90%)
M.Cap ( in Cr)
7178.57
Sanofi India (BSE)
 7023.75 (5.40%)
M.Cap ( in Cr)
16176.13
Astrazeneca Pharma I (BSE)
 2694.10 (12.08%)
M.Cap ( in Cr)
6735.25
Torrent Pharma (BSE)
 2361.35 (13.68%)
M.Cap ( in Cr)
39956.10
Shareholding Pattern More
MUTUAL FUNDS/UTI 9.29 %
FI/BANKS/INSURANCE 5.71 %
PROMOTERS 26.76 %
NON-INSTITUTION 13.8 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes